Live
FierceBiotechGSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive diseaseEndpoints NewsGSK spells out positive Phase 3 data for hepatitis B drug it licensed from IonisLabiotechLab Thread: integrating workflows to replace fragmented systemseLifeLanguage acquisition in newborns10x Genomics Blog10x genomics CEO Serge Saxonov sells $709,057 in shares - Investing.com10x Genomics Blog10x genomics president Hindson sells $283,399 in company stock - Investing.com10x Genomics Blog10x Genomics (NASDAQ: TXG) CEO sells 28,893 shares under 10b5-1 tax-related plan - Stock Titan10x Genomics Blog10x Genomics (TXG) officer sells 11,595 shares to cover RSU taxes - Stock TitanClinical OMICsPrecision, Gene-Edited Antimicrobial Targets Difficult-to-Treat E. ColiClinical OMICsLargest Rare Variant–Lipid Association Study Finds Heart Disease TargetsClinical OMICsWomen’s Memory Decline Linked to ECM Changes from Brain Estrogen LossClinical OMICsVirtual Reality Could Pinpoint Early Signs of Alzheimer’s
Illumina Feb 27, 2026

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida - Illumina

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida - Illumina

Body unavailable. Use the original source.